WO2023101616A1 - Composition and method for manufacturing nasal spray solution for the treatment and prevention of covid-19 - Google Patents
Composition and method for manufacturing nasal spray solution for the treatment and prevention of covid-19 Download PDFInfo
- Publication number
- WO2023101616A1 WO2023101616A1 PCT/TH2022/050009 TH2022050009W WO2023101616A1 WO 2023101616 A1 WO2023101616 A1 WO 2023101616A1 TH 2022050009 W TH2022050009 W TH 2022050009W WO 2023101616 A1 WO2023101616 A1 WO 2023101616A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- weight per
- covid
- per volume
- concentration
- Prior art date
Links
- 208000025721 COVID-19 Diseases 0.000 title claims abstract description 42
- 239000007922 nasal spray Substances 0.000 title claims abstract description 29
- 229940097496 nasal spray Drugs 0.000 title claims abstract description 29
- 230000002265 prevention Effects 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 title claims abstract description 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000008367 deionised water Substances 0.000 claims abstract description 7
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 239000002244 precipitate Substances 0.000 claims abstract description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 9
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 9
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 8
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 8
- 235000019800 disodium phosphate Nutrition 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims 1
- 241001678559 COVID-19 virus Species 0.000 abstract description 11
- 239000013543 active substance Substances 0.000 abstract description 2
- 239000004599 antimicrobial Substances 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 239000000872 buffer Substances 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 239000012929 tonicity agent Substances 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000003020 moisturizing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000288673 Chiroptera Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000010470 Ageusia Diseases 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000019666 ageusia Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the present invention relates to the field of pharmaceutical technology, in particular to the compositions and methods for manufacturing nasal spray solution for the treatment and prevention of COVID- 19. of the Invention
- COVID-19 or the Novel Coronavirus 2019 disease is a pandemic that began to spread in December 2019 through the contraction of a virus known as the Severe Acute Respiratory Syndrome Coronavirus or SARS-CoV-2.
- SARS-CoV-2 rapidly proliferated to other countries, until infected patients were found in almost every country worldwide.
- a study of the genetic materials of SARS-CoV-2 allowed researchers to establish that its nucleotides closely resembled those of a virus found in bats from China.
- SARS-CoV-2 had originated from a virus found in bats and mutated into strains, which could be spread from animals to humans, eventually leading to human-to-human transmission.
- COVID- 19 can be contracted by exposure to fine airborne droplets released by the respiratory system of patients. This exposure can arise from coughing or sneezing in the direction of other people and contact with the secretions of infected persons. Such secretions include saliva, nasal discharge, and phlegm.
- Contact with SARS-CoV-2 is also possible on the surfaces of various objects and appliances, as well as in the air via exposure through the eyes, nose and mouth.
- SARS-CoV-2 can persist on a wide variety of surfaces for a period of 2 hours to as long as 9 days. Nevertheless, it has been determined that SARS-CoV-2 is rapidly destroyed when exposed to UV radiation from sunlight.
- SARS-CoV-2 can also remain on surfaces or in the air for extensive periods at room temperature and below, especially in areas with low relative humidity.
- B cells white blood cells
- These antibodies are produced around 7-10 days after the body’s exposure to disease or foreign contaminants.
- therapeutic antibodies antibodies specific to the disease
- the immunity acquired from such an approach has been termed as “instant immunity”.
- COVID-19 is a disease that causes severe irregularities in the respiratory system. Commonly encountered symptoms of COVID-19 include fever, dry cough, drowsiness, nasal congestion, conjunctivitis, sore throat, headache, myalgia, skin rash, nausea, vomiting, diarrhea, shivering, and the loss of taste and smell. In some cases, severe symptoms such as hyperventilation and chest pain can be encountered. Complications such as respiratory system failure, acute respiratory illness, blood infection, thrombosis and damage to the heart, liver or kidneys may also arise. The COVID- 19 virus normally congregates in large colonies within the nasopharyngeal region. Therefore, the present invention has developed a formulation of nasal spray solution, comprising antibodies derived from the B cells of CO VID- 19 patients, for the treatment and prevention of COVID-19 by delivering said antibodies to the desired sites. of the Invention
- the present invention relates to a composition and method for manufacturing nasal spray solution for the treatment and prevention of COVID- 19.
- the nasal spray solution comprises antibodies obtained from the B cells of COVID-19 patients, wherein the antibodies constitute important active agents for inhibiting SARS-CoV-2.
- This solution also uses hydroxypropyl methylcellulose E 15LV to increase viscosity; sodium chloride as a tonicity agent; sodium phosphate dibasic and sodium phosphate monobasic as buffers for maintaining the solution’s pH within the range of 4-8; glycerin to increase the moisture levels of the nasal tissue; benzalkonium chloride as an antimicrobial agent; and deionized water as a solvent for said composition.
- the method for manufacturing the nasal spray solution involves adding water to the foregoing substances and blending them for 1 hour at a temperature of 60-70 degrees Celsius. The resultant solution is then kept at room temperature. After the temperature of the solution drops to 20-30 degrees Celsius, antibodies extracted from the B cells of COVID- 19 patients are added thereto and mixed thoroughly. Upon having mixed the antibodies, the solution is subjected to volume adjustment by using water to obtain 100 milliliters of nasal spray solution for the treatment and prevention of COVID-19.
- the purpose of the present invention is to develop a formulation for a nasal spray solution, comprising antibodies derived from the B cells of COVID- 19 patients, for the treatment and prevention of COVID- 19.
- the present invention possesses the characteristics of a clear solution, which is devoid of precipitates and exhibits high stability. Such attributes are considered beneficial for the treatment and prevention of COVID-19.
- a composition of the nasal spray solution for the treatment and prevention of COVID-19 comprises: antibodies derived from the B cells of COVID-19 patients at a concentration of 0.01- 0.1% by weight per volume, hydroxypropyl methylcellulose E 15LV at a concentration of 1.0-10.0% by weight per volume, sodium chloride at a concentration of 0.1-1.0% by weight per volume, sodium phosphate dibasic at a concentration of 0.1-10% by weight per volume, sodium phosphate monobasic at a concentration of 1-5% by weight per volume, glycerin at a concentration of 1.0-5.0% by weight per volume, benzalkonium chloride at a concentration of 0.01-0.05% by weight per volume, and deionized water for adjusting the volume of the composition to 100 milliliters, wherein the preferred composition of the nasal spray solution for the treatment and prevention of COVID-19 compries 3% concentration of hydroxypropylmethyl cellulose E 15LV by weight per volume, 0.22% concentration of sodium chloride by weight per volume, 0.12% concentration of sodium
- the method for manufacturing the nasal spray solution for the treatment and prevention of COVID-19 entails the following steps:
- Example 1 The method for manufacturing 100 milliliters of nasal spray solution, comprising antibodies extracted from the B cells of COVID- 19 patients, for the treatment and prevention of COVID-19 includes the following steps: (a) Pour 70 milliliters of water into a mixing container and heat it to 60-70 degrees Celsius.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a composition and method for manufacturing a nasal spray solution for the treatment and prevention of COVID-19. The nasal spray solution comprises antibodies obtained from the B cells of COVID-19 patients, wherein the antibodies constitute important active agents for inhibiting SARS-CoV-2. This solution includes a viscosity agent, a tonicity agent, buffers for maintaining the solution's pH within the range of 4-8, a moisturizing agent for nasal tissue, an antimicrobial agent, and deionized water as a solvent. The method for manufacturing the nasal spray solution involves adding water to the foregoing substances, blending them, and keeping the resultant solution at room temperature. Next, antibodies found in the B cells of COVID-19 patients are added to the solution and mixed thoroughly. The solution is further subjected to volume adjustment by using water to obtain 100 milliliters of nasal spray solution for the treatment and prevention of COVID-19. Said nasal spray solution is clear, lacks precipitates and exhibits high stability, all of which are considered beneficial for the treatment and prevention of COVID-19.
Description
Detailed Description of the Invention Title of Invention
COMPOSITION AND METHOD FOR MANUFACTURING NASAE SPRAY SOUUTION FOR THE TREATMENT AND PREVENTION OF COVID-19
Field of the Invention
The present invention relates to the field of pharmaceutical technology, in particular to the compositions and methods for manufacturing nasal spray solution for the treatment and prevention of COVID- 19.
of the Invention
COVID-19 or the Novel Coronavirus 2019 disease is a pandemic that began to spread in December 2019 through the contraction of a virus known as the Severe Acute Respiratory Syndrome Coronavirus or SARS-CoV-2. First discovered at a seafood market in Wuhan, China, SARS-CoV-2 rapidly proliferated to other countries, until infected patients were found in almost every country worldwide. A study of the genetic materials of SARS-CoV-2 allowed researchers to establish that its nucleotides closely resembled those of a virus found in bats from China. Thus, it was hypothesized that SARS-CoV-2 had originated from a virus found in bats and mutated into strains, which could be spread from animals to humans, eventually leading to human-to-human transmission. Accordingly, COVID- 19 can be contracted by exposure to fine airborne droplets released by the respiratory system of patients. This exposure can arise from coughing or sneezing in the direction of other people and contact with the secretions of infected persons. Such secretions include saliva, nasal discharge, and phlegm. Contact with SARS-CoV-2 is also possible on the surfaces of various objects and appliances, as well as in the air via exposure through the eyes, nose and mouth. Moreover, SARS-CoV-2 can persist on a wide variety of surfaces for a period of 2 hours to as long as 9 days. Nevertheless, it has been determined that SARS-CoV-2 is rapidly destroyed when exposed to UV radiation from sunlight. In contrast, SARS-CoV-2 can also remain on surfaces or in the air for extensive periods at room temperature and below, especially in areas with low relative humidity.
When the human body is exposed to a disease or foreign contaminants, its immune system will create a type of protein known as antibodies, produced from white blood cells termed as B cells. These antibodies are produced around 7-10 days after the body’s exposure to disease or foreign contaminants. However, if the disease causes severe and abrupt symptoms, the body will be incapable of producing antibodies in time. In this instance, antibodies specific to the disease (known as “therapeutic antibodies”) can be administered to the patient immediately, in order to directly combat the infection. The immunity acquired from such an approach has been termed as “instant immunity”.
COVID-19 is a disease that causes severe irregularities in the respiratory system. Commonly encountered symptoms of COVID-19 include fever, dry cough, drowsiness, nasal congestion, conjunctivitis, sore throat, headache, myalgia, skin rash, nausea, vomiting, diarrhea, shivering, and the loss of taste and smell. In some cases, severe symptoms such as hyperventilation and chest pain can be encountered. Complications such as respiratory system failure, acute respiratory illness, blood infection, thrombosis and damage to the heart, liver or kidneys may also arise. The COVID- 19 virus normally congregates in large colonies within the nasopharyngeal region. Therefore, the present invention has developed a formulation of nasal spray solution, comprising antibodies derived from the B cells of CO VID- 19 patients, for the treatment and prevention of COVID-19 by delivering said antibodies to the desired sites. of the Invention
The present invention relates to a composition and method for manufacturing nasal spray solution for the treatment and prevention of COVID- 19. The nasal spray solution comprises antibodies obtained from the B cells of COVID-19 patients, wherein the antibodies constitute important active agents for inhibiting SARS-CoV-2. This solution also uses hydroxypropyl methylcellulose E 15LV to increase viscosity; sodium chloride as a tonicity agent; sodium phosphate dibasic and sodium phosphate monobasic as buffers for maintaining the solution’s pH within the range of 4-8; glycerin to increase the moisture levels of the nasal tissue; benzalkonium chloride as an antimicrobial agent; and deionized water as a solvent for said composition. The method for manufacturing the nasal spray solution involves adding water to the foregoing substances and blending them for 1 hour at a temperature of 60-70 degrees Celsius. The resultant solution is then kept at room temperature. After the temperature of the solution drops to 20-30 degrees Celsius, antibodies extracted from the B cells of COVID- 19
patients are added thereto and mixed thoroughly. Upon having mixed the antibodies, the solution is subjected to volume adjustment by using water to obtain 100 milliliters of nasal spray solution for the treatment and prevention of COVID-19.
The purpose of the present invention is to develop a formulation for a nasal spray solution, comprising antibodies derived from the B cells of COVID- 19 patients, for the treatment and prevention of COVID- 19. The present invention possesses the characteristics of a clear solution, which is devoid of precipitates and exhibits high stability. Such attributes are considered beneficial for the treatment and prevention of COVID-19.
Full Disclosure of the Invention
A composition of the nasal spray solution for the treatment and prevention of COVID-19, comprises: antibodies derived from the B cells of COVID-19 patients at a concentration of 0.01- 0.1% by weight per volume, hydroxypropyl methylcellulose E 15LV at a concentration of 1.0-10.0% by weight per volume, sodium chloride at a concentration of 0.1-1.0% by weight per volume, sodium phosphate dibasic at a concentration of 0.1-10% by weight per volume, sodium phosphate monobasic at a concentration of 1-5% by weight per volume, glycerin at a concentration of 1.0-5.0% by weight per volume, benzalkonium chloride at a concentration of 0.01-0.05% by weight per volume, and deionized water for adjusting the volume of the composition to 100 milliliters, wherein the preferred composition of the nasal spray solution for the treatment and prevention of COVID-19 compries 3% concentration of hydroxypropylmethyl cellulose E 15LV by weight per volume, 0.22% concentration of sodium chloride by weight per volume, 0.12% concentration of sodium phosphate dibasic by weight per volume, 1.14% concentration of sodium phosphate monobasic by weight per volume, 2.5% concentration of glycerin by weight per volume, 0.02% concentration of benzalkonium chloride by weight per volume, and
0.05% concentration of antibodies extracted from the B cells of COVID-19 patients by weight per volume.
The method for manufacturing the nasal spray solution for the treatment and prevention of COVID-19 entails the following steps:
(a) Pour 70-80 milliliters of water into a mixing container and heat it to 60-70 degrees Celsius.
(b) Sprinkle hydroxypropyl methylcellulose E 15LV at a concentration ranging from 1.0-10.0% by weight per volume into the solution (a).
(c) Add sodium chloride at a concentration ranging from 0.1 -1.0% by weight per volume to the solution (b).
(d) Add sodium phosphate dibasic at a concentration ranging from 0.1-10% by weight per volume to the solution (c).
(e) Add sodium phosphate monobasic at a concentration ranging from 1-5% by weight per volume to the solution (d).
(f) Add glycerin at a concentration ranging from 1.0-5.0% by weight per volume to the solution (e).
(g) Add benzalkonium chloride at a concentration ranging from 0.01-0.05% by weight per volume to the solution (f), and blend in a mixer at a speed of 1,000 RPMs for 1 hour at 60-70 degrees Celsius to obtain a clear solution without any precipitates.
(h) Place the clear solution (g) at room temperature. Once the solution’s temperature falls to 20-30 degrees Celsius, add the antibodies extracted from the B cells of COVID-19 patients at a concentration ranging from 0.01-0.1% by weight per volume and mix thoroughly.
(i) Adjust the volume of the solution (h) to 100 milliliters by using deionized water.
(j) The nasal spray solution for the treatment and prevention of COVID-19 is obtained.
Example 1 - The method for manufacturing 100 milliliters of nasal spray solution, comprising antibodies extracted from the B cells of COVID- 19 patients, for the treatment and prevention of COVID-19 includes the following steps:
(a) Pour 70 milliliters of water into a mixing container and heat it to 60-70 degrees Celsius.
(b) Sprinkle hydroxypropyl methylcellulose E 15LV at a concentration of 3% by weight per volume into the solution (a).
(c) Add sodium chloride at a concentration of 0.22% by weight per volume to the solution (b).
(d) Add sodium phosphate dibasic at a concentration of 0.12% by weight per volume to the solution (c).
(e) Add sodium phosphate monobasic at a concentration of 1.14% by weight per volume to the solution (d).
(f) Add glycerin at a concentration of 2.5% by weight per volume to the solution (e).
(g) Add benzalkonium chloride at a concentration of 0.02% by weight per volume to the solution (f), and blend in a mixer at a speed of 1,000 RPMs for 1 hour at 60-70 degrees Celsius to obtain a clear solution without any precipitates.
(h) Place the clear solution (g) at room temperature. Once the solution’s temperature falls to 20-30 degrees Celsius, add the antibodies extracted from the B cells of COVID-19 patients at a concentration of 0.05% by weight per volume and mix thoroughly.
(i) Adjust the volume of the solution (h) to 100 milliliters by using deionized water.
(j) The nasal spray solution for the treatment and prevention of COVID-19 is obtained.
Best Mode for Carrying Out the Invention
The best mode for carrying out the invention has already been stated under the sub-heading, “Full Disclosure of the Invention”.
Claims
1. A composition of nasal spray solution for the treatment and prevention of COVID-19, comprising: antibodies derived from the B cells of CO VID-19 patients at a concentration of 0.01-0.1% by weight per volume, hydroxypropyl methylcellulose E 15LV at a concentration of 1.0-10.0% by weight per volume, sodium chloride at a concentration of 0.1-1.0% by weight per volume, sodium phosphate dibasic at a concentration of 0.1-10% by weight per volume, sodium phosphate monobasic at a concentration of 1-5% by weight per volume, glycerin at a concentration of 1.0-5.0% by weight per volume, benzalkonium chloride at a concentration of 0.01-0.05% by weight per volume, and deionized water for adjusting the volume of the composition to 100 milliliters.
2. The composition of nasal spray solution for the treatment and prevention of COVID- 19 according to Claim 1, wherein the preferred concentration of antibodies extracted from the B cells of COVID- 19 patients is 0.05% by weight per volume.
3. The composition of nasal spray solution for the treatment and prevention of COVID- 19 according to Claim 1, wherein the preferred concentration of hydroxypropyl methylcellulose E 15LV is 3% by weight per volume.
4. The composition of nasal spray solution for the treatment and prevention of COVID- 19 according to Claim 1, wherein the preferred concentration of sodium chloride is 0.22% by weight per volume.
5. The composition of nasal spray solution for the treatment and prevention of COVID- 19 according to Claim 1, wherein the preferred concentration of sodium phosphate dibasic is 0.12% by weight per volume.
6. The composition of nasal spray solution for the treatment and prevention of COVID- 19 according to Claim 1, wherein the preferred concentration of sodium phosphate monobasic is 1.14% by weight per volume.
7. The composition of nasal spray solution for the treatment and prevention of COVID- 19 according to Claim 1, wherein the preferred concentration of glycerin is 2.5% by weight per volume.
8. The composition of nasal spray solution for the treatment and prevention of COVID- 19 according to Claim 1, wherein the preferred concentration of benzalkonium chloride is 0.02% by weight per volume.
9. A method for manufacturing nasal spray solution for the treatment and prevention of COVID-19, comprising the steps of: a. Pouring 70-80 milliliters of water into a mixing container and heating said water to 60-70 degrees Celsius; b. Sprinkling hydroxypropyl methylcellulose E 15LV at a concentration ranging from 1.0-10.0% by weight per volume into solution (a); c. Adding sodium chloride at a concentration ranging from 0.1-1.0% by weight per volume to solution (b); d. Adding sodium phosphate dibasic at a concentration ranging from 0.1-10% by weight per volume to solution (c); e. Adding sodium phosphate monobasic at a concentration ranging from 1-5% by weight per volume to solution (d); f. Adding glycerin at a concentration ranging from 1.0-5.0% by weight per volume to solution (e); g. Adding benzalkonium chloride at a concentration ranging from 0.01-0.05% by weight per volume to solution (f), and blending the solution with said concentration of benzalkonium chloride in a mixer at a speed of 1,000 RPMs for 1 hour at 60-70 degrees Celsius to obtain a clear solution without any precipitates; h. Placing the clear solution (g) at room temperature and thoroughly mixing into said solution the antibodies, extracted from the B cells of COVID- 19 patients,
at a concentration ranging from 0.01-0.1% by weight per volume, once the temperature of said solution falls to 20-30 degrees Celsius; i. Adjusting the volume of solution (h) to 100 milliliters by using deionized water; and j. Obtaining the nasal spray solution for the treatment and prevention of CO VID -
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TH2103003570 | 2021-12-03 | ||
| TH2103003570U TH2103003570C3 (en) | 2021-12-03 | Composition and production process of nasal solution for the treatment and prevention of COVID-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023101616A1 true WO2023101616A1 (en) | 2023-06-08 |
Family
ID=84820028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TH2022/050009 WO2023101616A1 (en) | 2021-12-03 | 2022-11-24 | Composition and method for manufacturing nasal spray solution for the treatment and prevention of covid-19 |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023101616A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0769299A1 (en) * | 1995-04-24 | 1997-04-23 | Taiho Pharmaceutical Company, Limited | Remedy for allergic diseases in the region of the nose |
| WO2004002404A2 (en) * | 2002-06-28 | 2004-01-08 | Nastech Pharmaceutical Company Inc. | Compositions and method for enhanced mucosal delivery of interferon beta |
-
2022
- 2022-11-24 WO PCT/TH2022/050009 patent/WO2023101616A1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0769299A1 (en) * | 1995-04-24 | 1997-04-23 | Taiho Pharmaceutical Company, Limited | Remedy for allergic diseases in the region of the nose |
| WO2004002404A2 (en) * | 2002-06-28 | 2004-01-08 | Nastech Pharmaceutical Company Inc. | Compositions and method for enhanced mucosal delivery of interferon beta |
Non-Patent Citations (1)
| Title |
|---|
| FENWICK C. ET AL.: "A highly potent antibody effective against SARS-CoV-2 variants of concern", CELL REPORTS, vol. 37, no. 2, 12 October 2021 (2021-10-12), pages 1 - 19, XP055968598, DOI: 10.1016/j.celrep.2021.109814 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI624280B (en) | Nasal influenza vaccine composition | |
| CA2992352C (en) | Stuffy nose deblocking composition having antiviral activity | |
| CN109010825B (en) | Vagina in-situ gel preparation and preparation method and application thereof | |
| CN115721726B (en) | Nasal product for preventing or relieving cold symptoms and preparation method thereof | |
| US9662382B2 (en) | Vaccine to protect a ruminant against pneumonia caused by pasteurella multocida | |
| CN105919981A (en) | Defervescence patch and preparation process thereof | |
| JPS59227826A (en) | Antiallergic drug for local administration | |
| WO2023101616A1 (en) | Composition and method for manufacturing nasal spray solution for the treatment and prevention of covid-19 | |
| DE2423129A1 (en) | PROCESS FOR THE PRODUCTION OF TEMPERATURE SENSITIVE, NON-PATHOGENIC MUTANT STRAINS OF BOVINE ADENO VIRUS STRAINS AND LIVE VACCINES CONTAINING THESE VIRUS STRAINS | |
| CN100425288C (en) | Nasal cavity spraying inactivated influenza virus vaccine and its prepn process | |
| KR101245029B1 (en) | Vaccine composition for Korean Porcine reproductive and respiratory syndrome virus | |
| KR20060129221A (en) | Monoparamunity inducers based on attenuated rabbit myxoma viruses | |
| CN106236925B (en) | A kind of Chinese medicine inhalation aerosol and the preparation method and application thereof for treating asthma | |
| US11491219B2 (en) | Nasal hepatitis B vaccine composition and method for producing same | |
| HUP9801835A2 (en) | Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical composition | |
| KR20230066356A (en) | Virus infection prevention combination preparation and its manufacturing/use method and use | |
| CN108653729B (en) | Vaginal foaming agent and application thereof | |
| CN113350487A (en) | Antiviral composition and preparation method and application thereof | |
| US20220362190A1 (en) | Viral inactivation spray and gargling formulation | |
| Pappagianis et al. | Coccidioidomycosis naturally acquired by a monkey, Cercocebus atys, in Davis, California | |
| WO2024104313A1 (en) | Composition for antiviral or oxidation pretreatment, preparation method and usage method thereof | |
| RU2773357C2 (en) | Nasal vaccine composition against hepatitis b and its production method | |
| TH2103003570C3 (en) | Composition and production process of nasal solution for the treatment and prevention of COVID-19 | |
| TWI772097B (en) | Human thermosensitive adjuvant and preparation method thereof | |
| EP0914141A1 (en) | Stabilized antihepatitis-b vaccine tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22836354 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |